An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

Trial Profile

An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Feb 2016

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Expanded access
  • Acronyms DCVax-L EAP
  • Sponsors Northwest Biotherapeutics
  • Most Recent Events

    • 27 Mar 2015 Survival data in 51 patients published in Northwest Biotherapeutics media release.
    • 27 Mar 2015 Survival data in 51 patients presented at 2nd Immunotherapy of Cancer (ITOC) Conference in Germany, according to a Northwest Biotherapeutics media release.
    • 19 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top